
Free Daily Podcast Summary
by Pharma and BioTech News
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech. Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences. Produced by OWITH.ai , a boutique AI & data studio.
The most recent episodes — sign up to get AI-powered summaries of each one.
Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care. Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist pla...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of dynamic and significant advancements across the industry, from strategic acquisitions to regulatory shifts and scientific innovations. In a bold move, Novartis has acquired Sironax's blood-brain barrier delivery platform for $125 million. This acquisition marks a strategic enhancement in Novartis's ability to deliver therapi...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant strides and strategic maneuvers reshaping the landscape of healthcare and drug development. Kicking things off, GlaxoSmithKline (GSK) has made headlines with its acquisition of Chimagen Biosciences' trispecific T cell engager technology, targeting multiple myeloma. This move, valued at up to $750 million, highlights ...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today’s episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care. Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal m...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. First, let's delve into the innovative work being done by Grove Biopharma. Founded in 2020 in Chicago, this company is at the forefront of developing polymer-peptide hybrids to target intracellular protein-protein interactions, areas traditionally deemed undruggable. These interactions are crucial regulatory components in numerous cellular processes and are imp...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant advancements and challenges that are shaping the future of drug development, regulatory landscapes, and industry innovations. Starting with a major milestone in personalized cancer therapy, the FDA has expanded Bayer's approval for Hyrnuo (zipalertinib) to include its use as a first-line treatment for HER2-mutant non-small c...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself ...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to t...
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
Listeners also like.

Bloomberg Tech
Daily news and analysis on global tech companies, innovation, and the future of business.

Morning Brew Daily
A daily breakdown of business, economic, and general news with a witty and informative approach to start your day.

The Anthropic AI Daily Brief
Breaks down Anthropic's latest AI advancements and their real-world implications in clear, accessible language.

The Best One Yet
Daily business news explained through sharp analysis and witty commentary, delivered in concise 20-minute episodes.

Everyday AI Podcast – An AI and ChatGPT Podcast
Practical AI and ChatGPT tips for professionals to improve productivity and grow their careers.

The AI Daily Brief: Artificial Intelligence News and Analysis
A daily analysis of artificial intelligence news, exploring its creative potential, industry impacts, and ethical challenges.

TBPN
A daily live tech talk show featuring interviews with major figures in Silicon Valley and the tech industry.

The Digital Executive
A daily tech podcast exploring emerging technologies through interviews with Silicon Valley CEOs, influencers, and celebrities.

Bloomberg Intelligence
Analysis of Wall Street investments and company research from Bloomberg Intelligence experts.

The Daily
A daily news podcast covering major global stories with in-depth reporting from The New York Times.

Bloomberg Intelligence
Market analysis and financial insights from Bloomberg experts and newsmakers as Wall Street opens.

Stock Movers
Daily analysis of top-performing and struggling stocks across global markets, covering major sectors and breaking investment news.
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech. Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences. Produced by OWITH.ai , a boutique AI & data studio.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from Pharma and BioTech Daily in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of Pharma and BioTech Daily as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Pharma and BioTech News.
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
Pharma and BioTech Daily publishes daily. Our AI generates a summary within hours of each new episode.
Pharma and BioTech Daily covers topics including Science, News, Business, Investing, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.